

# Avacopan

## Adjudication Guideline

**Rule Category:**  
Pharmaceutical

**Ref: No:**  
2024-PH-0035

**Version Control:**  
Version No 2.0

**Effective Date:**  
15/04/2024

**Revision Date:**  
30/07/2026

**Approved by:**  
Daman

**Responsible:**  
Pharmacy Standards &  
Governance

**Related Adjudication  
Guidelines:**  
N/A

## Table of Contents

|                                           |   |
|-------------------------------------------|---|
| 1. Abstract .....                         | 3 |
| 1.1 For Members .....                     | 3 |
| 1.2 For Medical Professionals .....       | 3 |
| 2. Scope .....                            | 3 |
| 3. Adjudication Policy .....              | 3 |
| 3.1 Eligibility / Coverage Criteria ..... | 3 |
| 3.2 Requirements for Coverage .....       | 3 |
| 3.3 Non-Coverage .....                    | 4 |
| 3.4 Payment and Coding Rules .....        | 4 |
| 4. Denial Codes .....                     | 5 |
| 5. Appendices.....                        | 5 |
| 5.1 References .....                      | 5 |
| 5.2 Revision History .....                | 5 |

## Abstract

### 1.1 For Members

Avacopan is a medication used for the treatment of granulomatosis with polyangiitis (Wegener's Granulomatosis) and microscopic polyangiitis, conditions which body attacks its own veins and other blood vessels that can cause damage to organs.

### 1.2 For Medical Professionals

Avacopan is in a class of medications called complement inhibitors.

Treatment with Avacopan is given in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in combination with standard therapy including glucocorticoids.

## Scope

Scope of this adjudication rule is to highlight the medical indications, and coverage details of Avacopan as per policy terms and conditions of each health insurance plan administered by Daman.

## Adjudication Policy

### 1.3 Eligibility / Coverage Criteria

Avacopan is a medication used to treat granulomatosis with polyangiitis and microscopic polyangiitis.

### 1.4 Requirements for Coverage

- Eligible clinician specialities.
- ICD must be coded to the highest level of specificity.
- The safety and efficacy of avacopan in children below 17 years of age have not yet been established. No data are available.
- History of Medication use must be documented.
- Lab tests should be provided in medical report documentation and should be within recommended limits.

| Eligible clinician speciality    |
|----------------------------------|
| Internal Medicine                |
| Endocrinology/Metabolic Medicine |
| Nephrology                       |
| Immunology                       |
| Rheumatology                     |
| Pulmonology                      |
| Hematology/Oncology              |

#### Screening and lab tests required:

| Test                           |
|--------------------------------|
| Hepatitis B virus test Antigen |
| Total bilirubin                |
| ALT                            |
| AST                            |
| WBC                            |
| Neutrophils                    |
| Lymphocytes                    |

## 1.5 Non-Coverage

Visitor plan

## 1.6 Payment and Coding Rules

Kindly apply regulator payment rules and regulations and relevant coding manuals for ICD, Drugs.

## Denial Codes

| Code     | Code Description                                                                                                        |
|----------|-------------------------------------------------------------------------------------------------------------------------|
| CODE-014 | Activity/diagnosis is inconsistent with the patient's age/gender                                                        |
| MNEC-005 | Service/supply may be appropriate, but too frequent                                                                     |
| CODE-010 | Activity/diagnosis inconsistent with clinician specialty                                                                |
| MNEC-004 | Service is not clinically indicated based on good clinical practice, without additional supporting diagnoses/activities |
| AUTH-001 | Prior approval is required and was not obtained                                                                         |

## Appendices

### 1.7 References

[Overview | Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis | Guidance | NICE](#)  
[Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis \(nice.org.uk\)](#)  
[Granulomatosis with polyangiitis - Treatment algorithm | BMJ Best Practice label \(fda.gov\)](#)  
<https://www.medicines.org.uk/emc/product/13744/smpc#gref>  
[MabThera 100 mg Concentrate for Solution for Infusion - Summary of Product Characteristics \(SmPC\) - \(emc\) \(medicines.org.uk\)](#)  
[label \(fda.gov\)](#)

### 1.8 Revision History

| Date       | Version No. | Change(s)   |
|------------|-------------|-------------|
| 01.04.2024 | V1.0        | New Version |
| 30/7/2026  | V2.0        | No changes  |
|            |             |             |

## Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by The National Insurance Company – Daman (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.

